Abstract
This Health Industry Insights report examines the state of high-level systems
biology modeling adoption within the pharmaceutical industry, the progress and
prospects for modeling technology providers, and key applications for
high-level modeling throughout drug discovery and development. Access to
high-level systems biology modeling enables researchers to interactively
leverage accumulated biological knowledge in the form of biological pathways
and systems and to rapidly characterize and predict drug effects and identify
associated biomarkers.
The technology is achieving success stories with early adopters, including
major players such as Pfizer, Johnson & Johnson, and Novartis. Wider adoption
remains measured, but awareness is growing rapidly as demonstrated by rising
PubMed citations, FDA efforts to stimulate modeling and simulation, and
increasing public disclosure of promising results by early adopters. Building
on these published successes by early adopters, broad adoption of high-level
systems biology modeling is expected to occur over the next five years.
"While it's not yet possible to fully simulate human biology, current efforts
in high-level systems biology modeling demonstrate significant progress toward
that goal," said Alan Louie, Ph.D., research director for Health Industry
Insights.
View Cart
